Net product sales — Total revenues
Neurocrine Biosciences Net product sales — Total revenues increased by 1.6% to $811.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 43.9%, from $563.70M to $811.00M. Over 4 years (FY 2021 to FY 2025), Net product sales — Total revenues shows an upward trend with a 27.0% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates strong market demand and successful commercial execution of the product portfolio, while a decrease may signal competitive pressure, patent expirations, or market saturation.
Detailed definition
This metric represents the total gross revenue generated from the sale of pharmaceutical products, net of allowances, re...
Peer comparison
This is a standard top-line metric for biopharmaceutical companies, comparable to 'Net Product Revenue' or 'Product Sales' reported by peers in the specialty pharma and biotech sectors.
nbix_segment_net_product_sales_total_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $266.80M | $288.80M | $303.50M | $305.00M | $352.00M | $379.30M | $404.60M | $415.30M | $446.30M | $491.80M | $507.20M | $509.00M | $583.80M | $616.60M | $621.20M | $563.70M | $682.00M | $789.90M | $798.30M | $811.00M |
| QoQ Change | — | +8.2% | +5.1% | +0.5% | +15.4% | +7.8% | +6.7% | +2.6% | +7.5% | +10.2% | +3.1% | +0.4% | +14.7% | +5.6% | +0.7% | -9.3% | +21.0% | +15.8% | +1.1% | +1.6% |
| YoY Change | — | — | — | — | +31.9% | +31.3% | +33.3% | +36.2% | +26.8% | +29.7% | +25.4% | +22.6% | +30.8% | +25.4% | +22.5% | +10.7% | +16.8% | +28.1% | +28.5% | +43.9% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's net product sales — total revenues?
- Neurocrine Biosciences (NBIX) reported net product sales — total revenues of $811.00M in Q1 2026.
- How has Neurocrine Biosciences's net product sales — total revenues changed year-over-year?
- Neurocrine Biosciences's net product sales — total revenues increased by 43.9% year-over-year, from $563.70M to $811.00M.
- What is the long-term trend for Neurocrine Biosciences's net product sales — total revenues?
- Over 4 years (2021 to 2025), Neurocrine Biosciences's net product sales — total revenues has grown at a 27.0% compound annual growth rate (CAGR), from $1.09B to $2.83B.
- What does net product sales — total revenues mean?
- The total revenue earned from selling the company's pharmaceutical products after accounting for discounts and returns.